Selecta Biosciences anticipates the interim results during Q4 of 2019. The primary endpoint, a reduction in SUA level, is a proven rapid efficacy measure for gout treatment.1,2
References: 1. Clinicaltrials.gov NCT02959918. 2. Zhang W, Doherty, M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.